After Final Office Action of June 30, 2009

**AMENDMENTS TO THE CLAIMS** 

1. (Previously Presented) A method of treating or remedying psoriasis in a subject in

need thereof, comprising administering to the subject a therapeutically effective dose of at least

one calcitonin gene-related peptide (CGRP) antagonist compound in a pharmaceutically

acceptable formulation.

2. (Previously Presented) The method according to claim 1, wherein the at least one

CGRP antagonist compound is selected from the group consisting of: 4-sulfinyl benzamide

compounds, 3,4-dinitrobenzamide compounds, benzamidazolinyl piperadine compounds, anti-

CGRP antibodies, a peptide comprising SEQ ID NO:1, tryptase active polypeptide,

BIBN4096BS, and heparin.

3. (Previously Presented) The method according to claim 1, wherein the at least one

CGRP antagonist compound is administered locally.

4. (Cancelled)

5. (Original) The method according to claim 1, wherein the CGRP antagonist compound

2

is administered topically.

6-14. (Cancelled)

MAA/SAW/smi

Docket No.: 3535-0138PUS1

Docket No.: 3535-0138PUS1

15. (Previously Presented) The method according to claim 1, wherein the at least one

CGRP antagonist is administered topically, dermally, intradermally, subcutaneously, via dermal

infusion, or via subcutaneous infusion.

16-17. (Cancelled)

18. (Previously Presented) The method according to claim 1, wherein said at least one

CGRP antagonist compound comprises a polypeptide of SEQ ID NO:1.

19. (Previously Presented) The method according to claim 1, wherein said at least one

CGRP antagonist compound consists essentially of a polypeptide of SEQ ID NO:1.

20. (Previously Presented) The method according to claim 1, wherein the at least one

CGRP antagonist compound is a CGRP peptide which lacks wild type CGRP activity and binds

to CGRP receptor.

21-22. (Cancelled)

23. (New) The method according to claim 1, wherein the at least one CGRP antagonist is

administered dermally, intradermally, subcutaneously, via dermal infusion, via subcutaneous

infusion, or via microdialysis.

3

MAA/SAW/smj

Application No. 10/524,104 Amendment dated March 22, 2010 After Final Office Action of June 30, 2009 Docket No.: 3535-0138PUS1

24. (New) The method according to claim 1, wherein the at least one CGRP antagonist compound is BIBN4096BS.

- 25. (New) The method according to claim 1, wherein the pharmaceutically acceptable formulation consists essentially of a CGRP antagonist and an excipient.
- 26. (New) The method according to claim 1, further comprising exposing the subject to UVB radiation and/or administering a cell division inhibitor to the subject.